Company news

Medicenna Therapeutics Corp. news in 2025

Medicenna Therapeutics Corp.'s news releases, calls and decks from 2025, newest first.

View company

Dr. Fahar Merchant acquires shares of Medicenna

December 15, 2025

Medicenna Updates MDNA11 Clinical Trial Results at the ESMO-IO Congress 2025, Further Bolstering its Anti-Tumor Activity in Advanced Solid Tumors

December 10, 2025

Medicenna Therapeutics to Host a Live Webinar with Q&A to Discuss Updated MDNA11 Clinical Data

December 9, 2025

Medicenna Therapeutics Reports Second Quarter Fiscal 2026 Financial Results and Provides a Corporate Update

November 13, 2025

Medicenna and Fondazione Melanoma Onlus Collaborate to Advance MDNA11 Before First-Line Therapy in a Randomized Neoadjuvant Combination Trial, “NEO-CYT”, in High-Risk, Surgically Resectable Stage III Melanoma

November 6, 2025

Updated MDNA11 Clinical Data from the ABILITY-1 Study to be Presented at the European Society for Medical Oncology (ESMO) Immuno-Oncology Congress 2025

October 23, 2025

Medicenna Therapeutics Announces Participation in Upcoming Conferences

October 20, 2025

ROTH to Host 4th Annual Healthcare Opportunities Conference on October 9 in New York City

October 1, 2025

Medicenna Therapeutics to Participate in the ROTH 4th Annual Healthcare Opportunities Conference

October 1, 2025

Medicenna Announces Results of Annual Meeting of Shareholders

September 25, 2025

Medicenna to Participate at the H.C. Wainwright 27th Annual Global Investment Conference

September 5, 2025

Medicenna Therapeutics Reports First Quarter Fiscal 2026 Financial Results and Operational Highlights

August 1, 2025

Medicenna Strengthens Intellectual Property Portfolio with Five Patents Granted for its IL-2 and IL-4 Superkines

July 31, 2025

Medicenna Therapeutics Reports Fiscal Year 2025 Financial Results and Operational Highlights

June 26, 2025

Presenting on Emerging Growth Conference 82 Day 1 on May 21; Register to live stream

May 20, 2025

Medicenna Presents Promising Preclinical Data from its First-in-Class Tumor Targeted and Conditionally Activated Anti-PD-1-IL-2 Bifunctional Superkine at the Annual 2025 AACR Meeting

April 30, 2025

Medicenna Presents Compelling Results from the ABILITY-1 Clinical Trial at the 2025 AACR Annual Meeting

April 28, 2025

Medicenna to Present at the 2025 Bloom Burton & Co. Healthcare Investor Conference

April 22, 2025

Medicenna to Present at Jones Healthcare and Technology Innovation Conference

April 1, 2025

Medicenna to Provide Clinical Update on the MDNA11 ABILITY-1 Trial at the Upcoming American Association for Cancer Research Annual Meeting

March 26, 2025

Medicenna Reports MDNA11’s Compelling Anti-Cancer Activity is Associated with Significant Expansion of ‘Stem-Like’ Cancer Fighting Immune Cells at the Inaugural AACR-Immuno-Oncology Conference and Provides ABILITY-1 Study Update

February 25, 2025

Medicenna Reports Third Quarter Fiscal 2025 Financial and Operational Results and Provides Anticipated Milestones

February 13, 2025

Decks in 2025